Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer

Lung cancer is a heterogeneous disease encompassing a wide array of genetic abnormalities. The MET receptor tyrosine kinase is altered in many lung cancers, especially non-small cell lung cancer (NSCLC), and clinical trials of MET inhibitors that are underway are documenting cases of acquired resist...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Kawada, Ichiro, Hasina, Rifat, Arif, Qudsia, Mueller, Jeffrey, Smithberger, Erin, Husain, Aliya N., Vokes, Everett E., Salgia, Ravi
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5841456/
https://ncbi.nlm.nih.gov/pubmed/24305878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-3583
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi